# ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study

> **NCT06609551** · PHASE3 · RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 312 (estimated)

## Conditions studied

- Colon Cancer
- Colon Cancer (Stage II &Amp;Amp;Amp; III)

## Interventions

- **DRUG:** 6-month adjuvant chemotherapy with 5-FU monotherapy
- **DRUG:** XELOX intensive treatment group

## Key facts

- **NCT ID:** NCT06609551
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-03
- **Primary completion:** 2029-12-31
- **Final completion:** 2034-12-31
- **Target enrollment:** 312 (ESTIMATED)
- **Last updated:** 2024-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06609551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06609551, "ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06609551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*